Unveiling the Protein Expression Patterns in Oral Lichen Planus and Leukoplakia Through Comparative Salivary Proteomics

Salivary Proteomic Comparison of Oral Lichen Planus and Oral Leukoplakia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07416318

Enrollment

Registered

2026-02-18

Start date

2024-12-25

Completion date

2025-04-02

Last updated

2026-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Leukoplakia, Oral Lichen Planus, Proteomics, Saliva

Keywords

Proteomics, Oral Lichen Planus, Oral Leukoplakia, Saliva, Pathogenesis, Biomarker

Brief summary

The goal of this observational study is to compare salivary proteome profiles in patients with Oral Lichen Planus (OLP), Oral Leukoplakia (OL), and healthy individuals without oral mucosal disease. The main questions it aims to answer are: 1. Do salivary protein expression patterns differ between patients with OLP, OL, and healthy controls? 2. Can specific differentially expressed proteins serve as potential biomarkers for distinguishing OLP and OL from each other and from healthy individuals? Researchers will compare salivary proteomic profiles from patients with OLP, patients with OL, and healthy controls to determine whether measurable differences in protein expression exist between the groups. Participants will: 1. Provide unstimulated saliva samples collected as part of the study protocol. 2. Undergo grouping based on clinical diagnosis (OLP, OL, or healthy control), after which samples will be pooled and analyzed using nano-liquid chromatography coupled with tandem mass spectrometry (nLC-MS/MS) and label-free protein quantification methods.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

29 Years to 71 Years

Healthy volunteers

Yes

Inclusion criteria

* Saliva samples from patients diagnosed with either OLP or OL were included in the study group. * Saliva samples from individuals with no dermatological or systemic diseases and no lesions in the oral mucosa were included in the control group.

Exclusion criteria

* Patients who were using corticosteroids or retinoids that could affect the mucosa either locally or systemically were excluded from the study. * Patients with hyposalivation or with any conditions or medications that could cause reduced salivary flow were also excluded from the study.

Design outcomes

Primary

Measure	Time frame
Quantitative differences in salivary protein expression profiles between OLP, OL, and healthy control groups measured using label-free nLC-MS/MS proteomic analysis.	Baseline (single study visit during saliva sample collection; no longitudinal follow-up)

Countries

Turkey (Türkiye)

Outcome results